Rachel Brem Resigns from the Board of Directors of iCAD, Inc., Effective as of January 7, 2019
January 11, 2019 at 09:03 pm
Share
On January 7, 2019, Dr. Rachel Brem resigned from the Board of Directors of iCAD, Inc., effective as of January 7, 2019. Dr. Brem served on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors of the Company at the time of her resignation.
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogramâs collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a womanâs breast anatomy from the mammogram image.
ICAD, INC. 
